Changshan Pharmaceutical (300255.SZ) released its 2023 annual report. The company's revenue was 1.41 billion yuan...
According to the Zhitong Finance App, Changshan Pharmaceutical (300255.SZ) released its 2023 annual report. The company's revenue was 1.41 billion yuan, a year-on-year decrease of 39.63%. The net loss attributable to shareholders of listed companies was $1.24 billion. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was $1,258 billion. The basic loss per share was $1.35.